The FDA and the COVID‐19: A political economy perspective
| Autor: | Raymond J. March |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Economics and Econometrics
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) media_common.quotation_subject bureaucracy pandemics COVID economics healthcare regulation 0502 economics and business Pandemic Health care health economics 050207 economics health care economics and organizations 050205 econometrics media_common Symposium Article N32 Health economics I18 business.industry 05 social sciences Perspective (graphical) Authorization N31 Food and Drug Administration Symposium Articles Political economy Bureaucracy Business |
| Zdroj: | Southern Economic Journal |
| ISSN: | 2325-8012 0038-4038 |
| Popis: | This article utilizes a political economy framework to examine how FDA regulations impacted the U.S. healthcare sector's ability to address COVID‐19. I specifically examine the developing COVID‐19 testing, the approval of the medication remdesivir, and COVID‐19 vaccines. By examining periods before and after the FDA issued Emergency Use Authorizations (EUAs), my analysis finds that the FDA's regulations enacted before the COVID‐19 pandemic began strongly restricted clinician and patient access to COVID‐19 testing, remdesivir treatment, and approving vaccines. After the FDA issued EUAs, the healthcare sector quickly adopted COVID‐19 testing and remdesivir with little evidence of negative consequences. These findings contribute to the economics literature examining the FDA and contemporary COVID‐19 policy research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text